Jonathan L Temte1, Andrew R Zinkel. 1. Department of Family Medicine, University of Wisconsin Medical School, Madison, Wis 53715, USA. jtemte@wingra.fammed.wisc.edu
Abstract
PURPOSE: Inhalational anthrax is an extremely rare infectious disease with nonspecific initial symptoms, thus making diagnosis on clinical grounds difficult. After a covert release of anthrax spores, primary care physicians will be among the first to evaluate cases. This study defines the primary care differential diagnosis of inhalational anthrax. METHODS: In May 2002, we mailed survey instruments consisting of 3 randomly chosen case vignettes describing patients with inhalational anthrax to a nationwide random sample of 665 family physicians. Nonrespondents received additional mailings. Physicians were asked to provide their most likely nonanthrax diagnosis for each case. RESULTS: The response rate was 36.9%. Diagnoses for inhalational anthrax were grouped into 35 diagnostic categories, with pneumonia (42%), influenza (10%), viral syndrome (9%), septicemia (8%), bronchitis (7%), central nervous system infection (6%), and gastroenteritis (4%) accounting for 86% of all diagnoses. Diagnoses differed significantly between cases that proved to be fatal and those that proved to be nonfatal. CONCLUSIONS: Inhalational anthrax resembles common diagnoses in primary care. Surveillance systems for early detection of bioterrorism events that rely only on diagnostic codes will be hampered by false-positive alerts. Consequently, educating frontline physicians to recognize and respond to bioterrorism is of the highest priority.
RCT Entities:
PURPOSE: Inhalational anthrax is an extremely rare infectious disease with nonspecific initial symptoms, thus making diagnosis on clinical grounds difficult. After a covert release of anthrax spores, primary care physicians will be among the first to evaluate cases. This study defines the primary care differential diagnosis of inhalational anthrax. METHODS: In May 2002, we mailed survey instruments consisting of 3 randomly chosen case vignettes describing patients with inhalational anthrax to a nationwide random sample of 665 family physicians. Nonrespondents received additional mailings. Physicians were asked to provide their most likely nonanthrax diagnosis for each case. RESULTS: The response rate was 36.9%. Diagnoses for inhalational anthrax were grouped into 35 diagnostic categories, with pneumonia (42%), influenza (10%), viral syndrome (9%), septicemia (8%), bronchitis (7%), central nervous system infection (6%), and gastroenteritis (4%) accounting for 86% of all diagnoses. Diagnoses differed significantly between cases that proved to be fatal and those that proved to be nonfatal. CONCLUSIONS: Inhalational anthrax resembles common diagnoses in primary care. Surveillance systems for early detection of bioterrorism events that rely only on diagnostic codes will be hampered by false-positive alerts. Consequently, educating frontline physicians to recognize and respond to bioterrorism is of the highest priority.
Authors: M M Wagner; F C Tsui; J U Espino; V M Dato; D F Sittig; R A Caruana; L F McGinnis; D W Deerfield; M J Druzdzel; D B Fridsma Journal: J Public Health Manag Pract Date: 2001-11
Authors: L Borio; D Frank; V Mani; C Chiriboga; M Pollanen; M Ripple; S Ali; C DiAngelo; J Lee; J Arden; J Titus; D Fowler; T O'Toole; H Masur; J Bartlett; T Inglesby Journal: JAMA Date: 2001-11-28 Impact factor: 56.272
Authors: Bushra Mina; J P Dym; Frank Kuepper; Raymond Tso; Carmina Arrastia; Irina Kaplounova; Hasan Faraj; Agnieszka Kwapniewski; Christopher M Krol; Mayer Grosser; Jeffrey Glick; Steven Fochios; Athena Remolina; Ljiljana Vasovic; Jeffrey Moses; Thomas Robin; Maria DeVita; Michael L Tapper Journal: JAMA Date: 2002-02-20 Impact factor: 56.272
Authors: Lydia A Barakat; Howard L Quentzel; John A Jernigan; David L Kirschke; Kevin Griffith; Stephen M Spear; Katherine Kelley; Diane Barden; Donald Mayo; David S Stephens; Tanja Popovic; Chung Marston; Sherif R Zaki; Jeanette Guarner; Wun-Ju Shieh; H Wayne Carver; Richard F Meyer; David L Swerdlow; Eric E Mast; James L Hadler Journal: JAMA Date: 2002-02-20 Impact factor: 56.272
Authors: J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins Journal: Emerg Infect Dis Date: 2001 Nov-Dec Impact factor: 6.883
Authors: Dennis J Baumgardner; Jonathan L Temte; Erin Gutowski; William A Agger; Howard Bailey; James K Burmester; Indrani Banerjee Journal: WMJ Date: 2011-04